HAP-E: Healthy Aging in People With Epilepsy Program

Sponsor

University of California, San Diego (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06052605

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to develop and test an educational program about dementia in older adults living with epilepsy. The main questions it aims to answer are:

Can providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors improve dementia knowledge and health literacy among older adults with epilepsy?
Can aging related education and resources improve quality of life among older adults with epilepsy?

Participants will:

Complete a 12-week group educational program.
Complete pre- and post-program evaluation.

Condition or Disease	Intervention/Treatment	Phase
Epilepsy	Behavioral: Healthy Aging in People with Epilepsy Program	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

90 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Healthy Aging in People With Epilepsy Program (HAP-E): Closing the Gap in Epilepsy Care

Anticipated Study Start Date :

Aug 1, 2024

Anticipated Primary Completion Date :

Jul 1, 2027

Anticipated Study Completion Date :

Jun 1, 2029

Arms and Interventions

Arm	Intervention/Treatment
Experimental: HAP-E Epilepsy Participants	Behavioral: Healthy Aging in People with Epilepsy Program This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.

Arm

Intervention/Treatment

Experimental: HAP-E Epilepsy Participants

Behavioral: Healthy Aging in People with Epilepsy Program

This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.

Outcome Measures

Primary Outcome Measures

Dementia Knowledge [Pre and Post intervention (3 months)]
Dementia Knowledge Assessment Tool was designed to measure change in knowledge of dementia including dementia and its progress, support, and care. It contains 21 true/false items.
Health literacy [Pre and Post intervention (3 months)]
Short Assessment of Health Literacy-English is an 18-item scale assessing adult's ability to read and understand common medical terms.
Health Related Quality of life [Pre and Post intervention (3 months)]
Quality of life in Epilepsy-31 is a self-report questionnaire assessing quality of life in individuals with epilepsy. It measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, physical function, pain, role limitations due to physical problems, health perception, and perceived problems with attention/concentration, language, memory.

Eligibility Criteria

Criteria

Ages Eligible for Study:

55 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Current diagnosis of epilepsy made by a neurologist, epileptologist, or internist/family medicine physician
Proficiency in English

Exclusion Criteria:

Dementia

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Califonia, San Diego	San Diego	California	United States	92093

Sponsors and Collaborators

University of California, San Diego

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Anny Reyes, Postdoctoral Fellow, University of California, San Diego

ClinicalTrials.gov Identifier:

NCT06052605

Other Study ID Numbers:

HAPE2023

First Posted:

Sep 25, 2023

Last Update Posted:

Sep 25, 2023

Last Verified:

Sep 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Epilepsy

Study Results

No Results Posted as of Sep 25, 2023